Trial Outcomes & Findings for Clinical Evaluation of a Silicone Hydrogel Daily Wear Monthly Replacement Contact Lens (NCT NCT04422990)

NCT ID: NCT04422990

Last Updated: 2022-03-29

Results Overview

Visual acuity (VA) was assessed for each eye individually with study lenses in place using a letter chart. VA was collected in Snellen and converted to logarithm minimum angle of resolution (logMAR). A logMAR value of 0 equates to 20/20 Snellen visual acuity (normal distance eyesight), with lower logMAR values indicating better visual acuity.

Recruitment status

COMPLETED

Study phase

NA

Target enrollment

158 participants

Primary outcome timeframe

Week 1 Follow-Up

Results posted on

2022-03-29

Participant Flow

Participants were recruited from 14 sites located in the United States.

Of the 158 enrolled, 11 subjects were not dispensed study lenses and were exited from the study as screen failures. This reporting group includes all subjects who were dispensed study lenses (147).

Unit of analysis: Eyes

Participant milestones

Participant milestones
Measure
Biofinity
Comfilcon A silicone hydrogel contact lenses worn in both eyes during waking hours only. Lenses were worn for a total of 3 months, with monthly planned replacement over the course of the study duration. CLEAR CARE was used for nightly contact lens cleaning and disinfection.
LID018869
Lehfilcon A silicone hydrogel contact lenses worn in both eyes during waking hours only. Lenses were worn for a total of 3 months, with monthly planned replacement over the course of the study duration. CLEAR CARE was used for nightly contact lens cleaning and disinfection.
Overall Study
STARTED
50 100
97 194
Overall Study
COMPLETED
47 94
96 192
Overall Study
NOT COMPLETED
3 6
1 2

Reasons for withdrawal

Reasons for withdrawal
Measure
Biofinity
Comfilcon A silicone hydrogel contact lenses worn in both eyes during waking hours only. Lenses were worn for a total of 3 months, with monthly planned replacement over the course of the study duration. CLEAR CARE was used for nightly contact lens cleaning and disinfection.
LID018869
Lehfilcon A silicone hydrogel contact lenses worn in both eyes during waking hours only. Lenses were worn for a total of 3 months, with monthly planned replacement over the course of the study duration. CLEAR CARE was used for nightly contact lens cleaning and disinfection.
Overall Study
Withdrawal by Subject
0
1
Overall Study
Travel
3
0

Baseline Characteristics

Clinical Evaluation of a Silicone Hydrogel Daily Wear Monthly Replacement Contact Lens

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Biofinity
n=49 Participants
Comfilcon A silicone hydrogel contact lenses worn in both eyes during waking hours only. Lenses were worn for a total of 3 months, with monthly planned replacement over the course of the study duration. CLEAR CARE was used for nightly contact lens cleaning and disinfection.
LID018869
n=92 Participants
Lehfilcon A silicone hydrogel contact lenses worn in both eyes during waking hours only. Lenses were worn for a total of 3 months, with monthly planned replacement over the course of the study duration. CLEAR CARE was used for nightly contact lens cleaning and disinfection.
Total
n=141 Participants
Total of all reporting groups
Age, Continuous
33.6 years
STANDARD_DEVIATION 9.7 • n=99 Participants
33.1 years
STANDARD_DEVIATION 10.8 • n=107 Participants
33.2 years
STANDARD_DEVIATION 10.4 • n=206 Participants
Sex: Female, Male
Female
36 Participants
n=99 Participants
61 Participants
n=107 Participants
97 Participants
n=206 Participants
Sex: Female, Male
Male
13 Participants
n=99 Participants
31 Participants
n=107 Participants
44 Participants
n=206 Participants
Ethnicity (NIH/OMB)
Hispanic or Latino
0 Participants
n=99 Participants
5 Participants
n=107 Participants
5 Participants
n=206 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
49 Participants
n=99 Participants
87 Participants
n=107 Participants
136 Participants
n=206 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
0 Participants
n=99 Participants
0 Participants
n=107 Participants
0 Participants
n=206 Participants
Race/Ethnicity, Customized
White
12 Participants
n=99 Participants
20 Participants
n=107 Participants
32 Participants
n=206 Participants
Race/Ethnicity, Customized
Black or African American
0 Participants
n=99 Participants
1 Participants
n=107 Participants
1 Participants
n=206 Participants
Race/Ethnicity, Customized
Chinese
31 Participants
n=99 Participants
61 Participants
n=107 Participants
92 Participants
n=206 Participants
Race/Ethnicity, Customized
Japanese
1 Participants
n=99 Participants
4 Participants
n=107 Participants
5 Participants
n=206 Participants
Race/Ethnicity, Customized
Korean
4 Participants
n=99 Participants
6 Participants
n=107 Participants
10 Participants
n=206 Participants
Race/Ethnicity, Customized
Other Asian
1 Participants
n=99 Participants
0 Participants
n=107 Participants
1 Participants
n=206 Participants

PRIMARY outcome

Timeframe: Week 1 Follow-Up

Population: PP: A predefined subset of subjects (those with BCVA of 20/20 or better in each eye at baseline/dispense) from another similar completed registration study, CLY935-C010 (NCT04178720) was combined with this study to attain adequate power for the planned hypothesis testing of the primary and secondary endpoints. This included 49 subjects from CLY935-C012 and 39 subjects from CLY935-C010 in the Biofinity group and 92 subjects from CLY935-C012 and 78 subjects from CLY935-C010 in the LID018869 group.

Visual acuity (VA) was assessed for each eye individually with study lenses in place using a letter chart. VA was collected in Snellen and converted to logarithm minimum angle of resolution (logMAR). A logMAR value of 0 equates to 20/20 Snellen visual acuity (normal distance eyesight), with lower logMAR values indicating better visual acuity.

Outcome measures

Outcome measures
Measure
Biofinity
n=176 eyes
Comfilcon A silicone hydrogel contact lenses worn in both eyes during waking hours only. Lenses were worn for a total of 3 months, with monthly planned replacement over the course of the study duration. CLEAR CARE was used for nightly contact lens cleaning and disinfection.
LID018869
n=340 eyes
Lehfilcon A silicone hydrogel contact lenses worn in both eyes during waking hours only. Lenses were worn for a total of 3 months, with monthly planned replacement over the course of the study duration. CLEAR CARE was used for nightly contact lens cleaning and disinfection.
Least Squares Mean Contact Lens Corrected Distance Visual Acuity (CLCDVA) at Week 1 Follow-Up
-0.06 logMAR
Standard Error 0.00
-0.06 logMAR
Standard Error 0.00

SECONDARY outcome

Timeframe: Week 1 Follow-Up

Population: PP: A predefined subset of subjects (those with BCVA of 20/20 or better in each eye at baseline/dispense) from another similar completed registration study, CLY935-C010 (NCT04178720) was combined with this study to attain adequate power for the planned hypothesis testing of the primary and secondary endpoints. This included 49 subjects from CLY935-C012 and 39 subjects from CLY935-C010 in the Biofinity group and 92 subjects from CLY935-C012 and 78 subjects from CLY935-C010 in the LID018869 group.

Visual acuity (VA) was assessed for each eye individually with study lenses in place using a letter chart. VA was collected in Snellen, with 20/20 Snellen visual acuity considered normal distance eyesight. Subjects achieving at least 20/20 Snellen in each eye, left and right, contributed to the analysis.

Outcome measures

Outcome measures
Measure
Biofinity
n=176 eyes
Comfilcon A silicone hydrogel contact lenses worn in both eyes during waking hours only. Lenses were worn for a total of 3 months, with monthly planned replacement over the course of the study duration. CLEAR CARE was used for nightly contact lens cleaning and disinfection.
LID018869
n=340 eyes
Lehfilcon A silicone hydrogel contact lenses worn in both eyes during waking hours only. Lenses were worn for a total of 3 months, with monthly planned replacement over the course of the study duration. CLEAR CARE was used for nightly contact lens cleaning and disinfection.
Percentage of Subjects Achieving CLCDVA 20/20 or Better in Each Eye at Week 1 Follow-Up
98.8 percentage of subjects
97.0 percentage of subjects

Adverse Events

Pre-Treatment

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Biofinity Ocular

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Biofinity Non-Ocular

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

LID018869 Ocular

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

LID018869 Non-Ocular

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

CDMA Project Lead, Vision Care

Alcon Research, LLC

Phone: 1-888-451-3937

Results disclosure agreements

  • Principal investigator is a sponsor employee Sponsor reserves the right of prior review of any publication or presentation of information related to the study.
  • Publication restrictions are in place

Restriction type: OTHER